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Abstract The epithelium is part of an integrated immune system where cytokines, toll-like receptors and their ligands,
and extracellular vesicles play a crucial role in initiating an innate immune response. IL-36c is a pro-inflammatory member
of the IL-1 family that is mainly expressed by epithelial cells, but regulation of its expression and release are only
beginning to be understood. Previous studies reported that IL-36c is abundant in recurrent respiratory papillomatosis, a rare
but devastating disease caused by human papillomaviruses (HPV) types 6 and 11, in which papillomas recurrently grow in
and block the airway. Despite the overexpression of IL-36c, papilloma tissues show no evidence of inflammation, possibly
due to suppression of its release by HPVs. We have used primary human foreskin keratinocytes as a model to study IL-36c
regulation in normal epithelial cells. Low doses of poly(I:C) mediate expression and release of IL-36c without inducing the
cell death reported by those using high doses. PKR, an enzyme required for inflammasome activation, does not contribute
to controlled release of IL36c. The keratinocytes secrete IL-36c in two forms, soluble and in extracellular vesicles. We
conclude that there are two separately regulated pathways for the controlled secretion of IL-36c from keratinocytes, which
could contribute to the modulation of both local and systemic immune responses to viruses and other pathogens.
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Recurrent respiratory papillomatosis (RRP) is a rare but
devastating disease in which papillomas recurrently grow
in and block the airway. RRP is caused by human papillomaviruses (HPVs), primarily types 6 and 11 [1, 2].
Papillomas are benign stratified squamous epithelial
tumors characterized by a hyperplastic suprabasal epithelium surrounding cords of connective tissues [3].
The epithelium is part of an integrated immune system
where cytokines, toll-like receptors (TLRs) and extracellular vesicles (EVs) play a crucial role in initiating innate
immune responses. Anomalies within this system can lead
toward disease. Patients with RRP respond to HPV antigens with a blunted adaptive immune response that is
biased toward a TH2-like phenotype [4–6]. This bias
appears to reflect an underlying innate defect [7]. However, when DeVoti et al. [4] analyzed the transcriptional
profile of matched sets of papilloma tissues and normal

Feinstein Institute for Medical Research Immunology (2015) 63:228–235

airway tissues from the same RRP patients, IL-36c was the
gene that was most consistently elevated in the papillomas. IL-36c is a pro-inflammatory member of the IL-1
family, made by keratinocytes in response to multiple
stimuli [8, 9]. It is highly expressed in psoriasis, an
immune-mediated inflammatory skin disease [10]. Despite
its clear inflammatory potential, there is no evidence for
inflammation in papilloma tissues. Resolving this paradox
first requires a better understanding of the regulation of
IL-36c expression and release in normal epithelial cells,
which is still quite limited [11]. In this study, we have
used foreskin keratinocytes, which are also stratified
squamous epithelial cells, as a model system to study the
normal process.
Because IL-36c lacks a signal sequence, it is not
directed to the endoplasmic reticulum for secretion [11,
12]. Several nonclassical pathways of IL-1b secretion have
been reported, including the inflammasome, secretory
lysosomes, and various extracellular vesicles (EVs) [13].
Lian et al. [14] reported that high concentrations of the tolllike receptor 3 agonist poly(I:C), an analog of doublestranded RNA, induce IL-36c expression and release
through inflammasome-mediated pyroptosis. We have
asked whether keratinocytes might be induced to express,
and possibly release, IL-36c through a different pathway
that does not involve cell death. Such alternate regulation
might explain the lack of evident inflammation in papilloma tissues.
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control. Experiments were done at least three times unless
otherwise noted.
Western blot analysis
Proteins were extracted as previously described [19]. IL-36c
levels were normalized to b-actin and expressed relative to
controls treated with solvent. Primary antibodies were antiIL-36c at 1:400 (R&D system, Minneapolis, MN), antiTSG101 at 1:2000 (Abcam, Cambridge, MA), and anti-b
actin at 1:5000 (Sigma, Saint Louis, MO). LI-COR secondary
antibodies were used at 1:500 for quantification by the
Odyssey infrared imaging system (LI-COR, Lincoln, NE).
Measurement of cytokine release
Keratinocyte-conditioned medium was analyzed by ELISA
for accumulation of released IL-36c. Studies in Figs. 2 and
3 were done with a kit from Aviscera Bioscience (Santa
Clara, CA), and those in Fig. 4 were done using a kit from
Sigma, Saint Louis, Missouri because there were problems
with the Avicera plates. Results were initially measured as
pg/ml and then normalized to the protein concentration in
the cell monolayer releasing the cytokine. IL-1b ELISA
was done using kits from R&D System (Minneapolis, MN).
All studies were done as per manufacturers’ directions.
EVs were isolated from conditioned medium as previously
described [18] and analyzed by western blot.

Materials and methods

Statistical analysis

Cell culture and reagents

Statistical analyses were performed with a one-way analysis of variance (ANOVA) with Tukey–Kramer multiple
comparisons test. P values \0.05 were considered significant; p values \0.001 were considered highly significant.

Neonatal human foreskins were obtained anonymously as
surgical discards. The North Shore-LIJ Institutional
Review Board determined that the study was exempt.
Keratinocyte cultures were established as described [15],
pooled, and expanded for no more than four passages on
mitomycin C-treated J2-3T3 feeder cells in E-media [16].
Cell viability was assessed by trypan blue exclusion and by
lactic dehydrogenase release as described [17]. For analysis
of EVs, cells were cultured in medium supplemented with
serum depleted of EVs as previously described [18]. For
in vitro stimulation and inhibition assays, the following
substances were used, at the concentrations shown and
times indicated in the text: poly(I:C) (Invivogen, San
Diego, CA), 2AP, 7DG, EGFR inhibitor (PD153035),
MEK inhibitor (PD98059), p38 inhibitor (SB202190), PI3 K inhibitor (LY294002) and JNK inhibitor (SP600125)
(all from Sigma, Saint Louis, Missouri). For all experiments, the solvent for the specific reagent was used as a

Results
We first determined that poly(I:C) could induce IL-36c
expression in a dose-dependent manner (Fig. 1a, b), at concentrations lower than those used by Lian et al. [14] which
causes subsequent cell death. IL-1b, the prototypical member
of the IL-1 family of which IL-36c is a member, was also
induced by poly(I:C) (Fig. 1c). To rule out the possibility that
the lower concentrations of poly(I:C) induced death of some
of the cells, we used both trypan blue staining and assay of
lactate dehydrogenase (LDH) in the culture medium. There
was no detectable cell death as measured by trypan blue
staining (not shown) or by LDH release (Fig. 1d). We were
also unable to detect any IL-1b in the conditioned medium
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Fig. 1 Low doses of poly(I:C) induce IL-36c expression. a Representative western blot showing IL-36c expression in keratinocytes
stimulated with increasing concentrations of poly(I:C) for 48 h. b
Quantification of intracellular IL-36c. Bars show mean ± SD,
relative to controls treated with vehicle (n = 6 experiments,
*p \ 0.001). c Representative western blot of keratinocytes treated

with vehicle or with poly(I:C) for 48 h. Recombinant IL-1b at 20 ng/
lane was used as a positive control. b-actin was used as a loading
control. d Cells were treated with increasing concentrations of
poly(I:C) for 96 h and the culture medium assayed for released lactic
dehydrogenase (LDH) as a measure of cell death. Culture medium
from cells lysed with the detergent NP40 served as a positive control

using a highly sensitive ELISA assay (data not shown), further evidence for the absence of any cell death.
Release of soluble IL-36c was induced by these same
lower concentrations of poly(I:C) (Fig. 2a). Soluble IL-36c
that accumulated in the medium could only be reliably
detected at 72 h after treatment and was much greater at
96 h (Fig. 2b), although intracellular IL-36c was markedly
elevated at 48 h. To further analyze the relationship between
kinetics of expression and release, the culture medium was
changed at 48 hours, with and without additional poly(I:C),
and IL-36c measured at 96 h post-initial treatment. The
additional 48 h of treatment with poly(I:C) had no effect on
intracellular IL-36c levels (Fig. 2c). Moreover, levels of IL36c were comparable whether poly(I:C) was added for only
the first 48 h or was re-added for the subsequent 48 h
(Fig. 2d). Together, these results suggest that the process of
release requires an extended period of time after initiation,
rather than simply being dependent on accumulation of
intracellular IL-36c, and the process does not require continuous stimulation with poly(I:C) once initiated.
Respiratory papilloma cells constitutively express both
activated MAP kinases [20, 21] and IL36c [7], and TLR3
activation can activate MAP kinases in multiple cell types
including keratinocytes [22–25]. We therefore asked whether activation of MAP kinases was required for the low
dose of poly(I:C)-induced expression or release of IL-36c

(Fig. 3a, b) in normal keratinocytes. Surprisingly, inhibiting
each of the MAPKs had no significant effect, although there
appeared to be a very modest reduction in IL-36c expression
with the p38 MAP kinase inhibitor. Western blots confirmed
that ERK activation was inhibited by the MEK inhibitor;
there was no measurable activation of p38 MAP kinase with
poly(I:C) and thus no detectable inhibition (data not shown).
Double-stranded RNA-dependent protein kinase (PKR)
regulates inflammatory responses by activating multiple
pathways, including the inflammasome [26], and PKR can
be directly activated by poly(I:C) [27]. IL-36c release was
inhibited by the kinase inhibitor 2AP, which is frequently
used as a PKR inhibitor, but not by the more selective PKR
inhibitor 7DG [28] (Fig. 4a). To confirm that 2AP was
inhibiting release and not simply affecting the expression of
IL-36c, we analyzed intracellular levels of IL-36c by western blot. There was no effect of 2AP on either baseline or
poly(I:C)-stimulated expression (Fig. 4b). We also considered the possibility that the dose of 7DG was insufficient to
block PKR activation. 7DG significantly inhibited inflammasome-mediated cell death induced by a higher concentration of poly(I:C), as measured by LDH release (Fig. 4c).
These results indicate that the controlled release of IL-36c
does not require activation of PKR or the inflammasome,
and suggest that one of the many other kinases inhibited by
2AP may mediate release of soluble IL-36c [29].
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Fig. 2 Low doses of poly(I:C) induce IL-36c release in a dose and
time-dependent manner. a Cells were treated with increasing
concentrations of poly(I:C) for 96 h, and the conditioned medium
analyzed by ELISA for accumulated IL-36c. Bars show mean ± SD
of IL-36c per lg of cellular protein in the secreting monolayer (n = 8
experiments, *p \ 0.001 relative to control cells treated with solvent).
b Cells were treated with 1500 ng/ml of poly(I:C) and conditioned
medium analyzed by ELISA at varying times. Bars show mean ± SD

of IL-36c levels, normalized per lg of cellular protein in the secreting
monolayer (n = 4 experiments, *p \ 0.001 compared to 0 time). c/d
Cells were treated with 1500 ng/ml of poly(I:C) for 48 h, the medium
removed, the cells washed, and medium replaced for an additional
48 h ± additional poly(I:C). Intracellular IL-36c was measured by
western blot (c) and IL-36c levels in the conditioned medium
measured by ELISA (d). Bars show mean ± SD of 4 experiments

Cells secrete EVs that can mediate cell–cell communication through exchange of both protein and RNA [30]. We
therefore asked whether IL-36c can be secreted within EVs
as well as in soluble form. Keratinocytes constitutively
secreted EVs, independently of poly(I:C) stimulation, as
demonstrated by the detection of TSG101 in EVs from the
untreated controls. However, EVs from cells treated with
poly(I:C) contained significantly more IL-36c (Fig. 5a, b).
The EVs did not contain detectable IL-1b, suggesting that
incorporation of IL-36c was specific. Unlike the release of
soluble IL-36c, secretion within EVs was not sensitive to
2AP (Fig. 5c), suggesting that these two processes are
regulated separately. Consistent with the finding that IL36c is within vesicles, immunohistochemical staining of
papilloma tissues showed that IL-36c was primarily
punctuated in appearance, and localized adjacent to the
cytoplasmic and nuclear membranes of cells in the spinous
layer (Fig. 5d). The level of expression in normal epithelial
tissue was too low to be detected (not shown).

Different cell types have been shown to release different
types of EVs, such as exosomes, ectosomes and
microvesicles [31]. To analyze the type of keratinocyte
EVs that contained IL-36c, we isolated the vesicles, separated them on sucrose gradients, and performed western
blots on each fraction (Fig. 5e). We used TSG101 as an
endosomal marker and the transferrin receptor as an exosomal marker. TSG101 is a major component protein of the
ESCRT machinery for exosome synthesis [32]. The transferrin receptor is a membrane carrier protein and was the
first transmembrane protein found to be released in exosomes [33]. TSG101 was present in fractions 1–4 (between
1.000 and 1.042 g/ml), and the transferrin receptor was
detectable in fractions 4–8 (between 1.042 and 1.180 g/
ml). Exosomes usually float at a density between 1.08 and
1.18 g/ml [34]. We detected IL-36c mainly in fractions 4, 5
and especially 6 (Fig. 5c), with lesser amounts in fractions
1–3, suggesting that IL-36c is secreted in multiple different
vesicles, but mainly associated with exosomes.
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3 h and then poly(I:C) (1500 ng/ml) was added for an additional 48 h
and IL-36c analyzed by western blot. IL-36c levels were normalized
to b-actin to correct for protein loading. Bars show mean ± SD,
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Fig. 4 2AP suppresses poly(I:C)-induced IL-36c release, while 7DG
has no effect on release. a Cells were stimulated for 96 h with
1500 ng/ml poly(I:C) ± the broad spectrum PKR inhibitor 2AP
(1 mM) or the more specific inhibitor 7DG (5 lM), and IL-36c
accumulation in the conditioned medium measured by ELISA. Bars
show mean ± SD of 5 experiments (*p \ 0.001 compared to control
cells treated with solvent, **p \ 0.001 compared to cells treated with
poly(I:C) but no inhibitor). b Cells were treated for 96 h with

1500 ng/ml poly(I:C) ± 2AP at the concentrations shown, and
intracellular IL-36c levels determined by western blot with b-actin
as a loading control. A representative blot is shown. c Cells were
treated with 2 lM poly(I:C) ± 5 lM 7DG for 96 h and the culture
medium assayed for released lactic dehydrogenase (LDH) as a
measure of cell death. 7DG suppressed the elevated cell death
induced by high-dose poly(I:C) (*p \ 0.001)

Discussion

that activate dendritic cells and Langerhans cells. Poly(I:C)
has been shown to induced cytokine expression in keratinocytes through activation of both TLR3 and RIG-1,
with the dsRNA-sensing kinase PKR playing a key role in
the signaling downstream of both receptors [35].

Keratinocytes are a key component of the innate immune
response, reacting to infection by bacteria or viruses with
expression of proinflammatory cytokines and chemokines
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Fig. 5 Poly(I:C) induces IL-36c release in multiple extracellular
vesicles (EVs), consistent with punctuate appearance of IL-36c in
suprabasal layers of papillomas. a Representative western blot. HFKs
were stimulated with 1500 ng/ml poly(I:C) for 96 h, vesicles isolated
by differential centrifugation, and analyzed by western blot using
TSG101 as a marker for EVs and as a loading control. b
Quantification of IL-36c within vesicles. Bars show mean ± SD,
relative to controls without poly(I:C) (n = 4 experiments,
*p \ 0.001). c Cells were treated with poly(I:C) ± 1 mM 2AP, and
EVs isolated and analyzed as in ‘‘a.’’ Bars show mean ± SD, relative

to controls of 4 experiments. d Sections of paraffin-imbedded
papilloma tissues were incubated with goat anti-IL-36c and visualized
with fluorescein-conjugated donkey anti-goat IgG. DAPI staining of
DNA was used as a counterstain. Images show representative
papilloma sections. Bars = 40 lm. e Cells were stimulated with
1500 ng/ml poly(I:C) for 96 h, extracellular vesicles were extracted
by differential centrifugation, separated on sucrose gradients and
fractions from the gradients analyzed by western blot. TSG101 is a
marker for endosomes and the transferrin receptor marks exosomes. A
representative blot is shown

Furthermore, poly(I:C) has been shown to induce expression of the proinflammatory cytokine IL-36c in keratinocytes and induce cytokine release through pyroptosis,
a form of inflammasome-mediated cell death [14]. PKR
played an essential role in both processes, and studies have
reported that PKR is required for inflammasome activation
[28]. Finally, Karim et al. [36] reported that HPV16 suppressed poly(I:C)-induced expression of a number of
proinflammatory genes, including components of the
inflammasome, proposing that this was a mechanism for
immune evasion by HPVs. However, all of those studies
used high concentrations of poly(I:C), which are lethal to
keratinocytes. Because massive cell death is not seen in
conjunction with HPV infection, we set out to determine
whether poly(I:C) could induce the expression and release
of IL-36c at sublethal concentrations.
In this study, we have shown that a low dose of
poly(I:C) induces expression and release of soluble IL-36c
in a PKR-independent process that causes no measurable
cell death. We estimate that approximately 5 % of the total
intracellular IL-36c accumulates in the culture medium.
This could well be an underestimate of actual secretion if

some of the IL-36c is degraded or binds to and is taken
back up by the keratinocytes. Future studies will be needed
to determine the pathway(s) that mediate expression, but
clearly they do not involve MAP kinase activation. This is
consistent with the report by Yu et al. [37] that poly(I:C)induced shedding of TNFR1 from airway epithelial cells is
independent of MEK, Erk, JNK and Akt. The protracted
period of time required for controlled release of soluble IL36c in our study was unexpected. Clearly, it did not reflect
a delay in transcription or translation since we were able to
detect high levels of intracellular IL-36c 24 hours after
poly(I:C) stimulation. Rather, we speculate that it reflects
the time required to induce and possibly assemble a
secretory mechanism that is yet to be determined.
We have also shown for the first time that IL-36c is
released from keratinocytes in multiple extracellular vesicles in response to poly(I:C) stimulation. Vesicular release
is independent of PKR, and also independent of the
unidentified kinase inhibited by 2AP that regulates soluble
IL-36c release. Our knowledge of the biogenesis and
secretion of EVs has grown extensively in the last decade.
The endosomal sorting complex required for transport is
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composed of four multi-protein complexes, ESCRT-0, 1, 2
and 3 and each has its own function in the biogenesis of
EVs [38]. There is significant variation in ESCRT composition and function in different cell types [39], and this
process has not been extensively studied in normal keratinocytes. However, studies in other cell types have shown
that the determination of cargo within EVs is controlled
and not random [32, 40, 41]. We have shown that EVs
released from poly(I:C)-stimulated keratinocytes contain
IL-36c but not IL-1b, suggesting an active sorting process
in response to poly(I:C) stimulation.
The ability of viable keratinocytes to release IL-36c in
both a soluble and an EV-encapsulated manner would
suggest that it should be released by papilloma cells since
they contain high intracellular levels, thus activating an
inflammatory response in the larynx of RRP patients. The
absence of inflammation, coupled with our finding that
release of soluble IL-36c is markedly delayed, suggests
that release of this cytokine is an active and regulated
process. HPV11 can suppress the release of soluble IL-36c
[7], and Honegger et al. [42] reported that HPV18 suppresses secretion of extracellular vesicles from HeLa cells.
Further studies will be needed to define the molecular
mechanism(s), whereby HPVs suppress the controlled
release of cytokines from keratinocytes.
We conclude that there are two separately regulated
pathways for the controlled release of IL-36c from keratinocytes, which might have different biological activity.
Future studies will be needed to characterize these pathways in detail and determine their role(s) in the modulation
of both local and systemic immune responses to infection.
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